Hypoglycemic effect of Talapotaka Churna in streptozotocin-induced hyperglycemia in rats

Abstract

Objective: To evaluate the antihyperglycemic effect of Talapotaka Churna in experimental animals, Talapotaka Churna was prepared, containing Avartaki (Cassia auriculata), Amalaki (Emblica officinalis), Haridra (Curcuma longa), and Daruharidra (Berberis aristata). Materials and Methods: Talapotaka Churna was prepared by the standard procedure of Churna Kalpana. Hyperglycemia was induced to create an equivalent to the diabetic state by giving streptozotocin (STZ) solution (intraperitoneal) 35 mg/kg. After assessment of hyperglycemia as an approximate induction of diabetes, group of animals (IV and V) were treated with doses 300 and 600 mg/kg of Talapotaka Churna. For treatment comparison, Group III animals were treated with a standard hypoglycemic drug, glibenclamide 10 mg/kg. Blood sugar, the level was estimated by glucometer on the 7th, 14th, 21st, and 28th day. Results: Talapotaka Churna produced a significantly lowering of fasting blood glucose with various doses in STZ-induced diabetic rats. In a 4-week study, Talapotaka Churna produced a significant reduction in blood glucose compared to glibenclamide. Conclusion: Talapotaka Churna and glibenclamide significantly lowered blood glucose level. The results were found more significant with respect to treatment days in this in vivo comparative study.